Andere Sprachen Scandion Oncology A/S

Aktien

A2N9BV

DK0061031895

SCOL

Verzögert Nasdaq Stockholm Andere Börsenplätze 09:41:20 27.06.2024			% 5 Tage	% 1. Jan.
0,29 ^SEK	0,00 %		-26,02 %	-92,74 %

22.05.	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
22.05.	Scandion Oncology A/S meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE	25.06.
Scandion announces change of Certified Adviser to Vator Securities	03.06.
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE	31.05.
Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension	27.05.
Scandion Oncology – Interim Report Q1 2024	22.05.
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	22.05.
Invitation to Scandion Oncology webcast and conference call May 22, 2024	16.05.
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101	13.05.
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	13.05.
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors	06.05.
Scandion Oncology to Host R&D Update May 15	03.05.
Scandion Oncology – Notice convening the Annual General Meeting	19.04.
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival	21.03.
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	21.03.
Scandion Oncology - Annual Report 2023	15.03.
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial	07.03.
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	07.03.
Scandion Oncology Q4 2023 - Striving towards randomised controlled data	01.03.
Scandion Oncology – Q4 & yearend report 2023	28.02.
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Scandion Oncology A/S

Aktien

A2N9BV

DK0061031895

SCOL

Andere Sprachen

Filter